Nested’s RAF/MEK molecular glue NST-628 cleared to enter clinic for solid tumors
March 28, 2024
Nested Therapeutics Inc. has obtained FDA clearance of its IND application for NST-628 for the treatment of patients with advanced solid tumors harboring genetic alterations in the RAS-MAPK pathway.
